# SAVANNAH (NCT03778229)

> Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03778229
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Carcinoma
- Interventions: osimertinib; savolitinib; placebo
- Enrollment: 367
- Primary outcome: Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set
- Primary outcome: Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=savannah-nct03778229